MedTrace Logo

A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

NCT06941350 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-04-23

No results posted yet for this study

Summary

Evaluate the safety and efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.

Conditions

  • Acute Graft-versus-Host Disease

Interventions

BIOLOGICAL

NCR102 injection

Twice a week for 4 weeks, and the treatment continues for another 4 weeks in subjects with partial remission by day 28.

Sponsors & Collaborators

  • Nuwacell Biotechnologies Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-28
Primary Completion
2026-10-30
Completion
2027-05-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06941350 on ClinicalTrials.gov